ImmuCell (ICCC) Competitors

ImmuCell logo
$11.33 -0.09 (-0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$11.22 -0.11 (-0.97%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ICCC vs. FENC, SPRY, AVIR, ACB, and ENTA

Should you buy ImmuCell stock or one of its competitors? ImmuCell's main competitors and comparable companies include Adherex Technologies (FENC), ARS Pharmaceuticals (SPRY), Atea Pharmaceuticals (AVIR), Aurora Cannabis (ACB), and Enanta Pharmaceuticals (ENTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ImmuCell compare to Adherex Technologies?

ImmuCell (NASDAQ:ICCC) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

ImmuCell has higher earnings, but lower revenue than Adherex Technologies. ImmuCell is trading at a lower price-to-earnings ratio than Adherex Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuCell$27.64M3.73-$1.04M$0.2056.65
Adherex Technologies$44.64M10.71-$9.74M$0.011,358.00

ImmuCell has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Adherex Technologies has a consensus target price of $17.25, suggesting a potential upside of 27.03%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than ImmuCell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Adherex Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00

ImmuCell has a net margin of 5.66% compared to Adherex Technologies' net margin of 2.52%. Adherex Technologies' return on equity of 8.96% beat ImmuCell's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuCell5.66% 6.25% 4.15%
Adherex Technologies 2.52%8.96%4.90%

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Adherex Technologies had 5 more articles in the media than ImmuCell. MarketBeat recorded 11 mentions for Adherex Technologies and 6 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.94 beat Adherex Technologies' score of 0.79 indicating that ImmuCell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmuCell
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adherex Technologies
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Adherex Technologies beats ImmuCell on 13 of the 17 factors compared between the two stocks.

How does ImmuCell compare to ARS Pharmaceuticals?

ImmuCell (NASDAQ:ICCC) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

ImmuCell has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

In the previous week, ImmuCell had 5 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 6 mentions for ImmuCell and 1 mentions for ARS Pharmaceuticals. ImmuCell's average media sentiment score of 0.94 beat ARS Pharmaceuticals' score of 0.91 indicating that ImmuCell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmuCell
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ARS Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ARS Pharmaceuticals has a consensus price target of $23.33, indicating a potential upside of 539.27%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than ImmuCell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
ARS Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

ImmuCell has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuCell$27.64M3.73-$1.04M$0.2056.65
ARS Pharmaceuticals$84.28M4.35-$171.30M-$2.02N/A

ImmuCell has a net margin of 5.66% compared to ARS Pharmaceuticals' net margin of -163.64%. ImmuCell's return on equity of 6.25% beat ARS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuCell5.66% 6.25% 4.15%
ARS Pharmaceuticals -163.64%-453.93%-71.62%

Summary

ImmuCell and ARS Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Atea Pharmaceuticals?

ImmuCell (NASDAQ:ICCC) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Atea Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 102.02%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Atea Pharmaceuticals is more favorable than ImmuCell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Atea Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

ImmuCell has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

In the previous week, ImmuCell had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for ImmuCell and 3 mentions for Atea Pharmaceuticals. ImmuCell's average media sentiment score of 0.94 beat Atea Pharmaceuticals' score of 0.56 indicating that ImmuCell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmuCell
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Atea Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ImmuCell has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuCell$27.64M3.73-$1.04M$0.2056.65
Atea PharmaceuticalsN/AN/A-$158.35M-$1.95N/A

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImmuCell has a net margin of 5.66% compared to Atea Pharmaceuticals' net margin of 0.00%. ImmuCell's return on equity of 6.25% beat Atea Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuCell5.66% 6.25% 4.15%
Atea Pharmaceuticals N/A -69.91%-61.22%

Summary

ImmuCell beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does ImmuCell compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

ImmuCell has a net margin of 5.66% compared to Aurora Cannabis' net margin of -23.70%. ImmuCell's return on equity of 6.25% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-23.70% 3.72% 3.03%
ImmuCell 5.66%6.25%4.15%

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 5.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aurora Cannabis has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
ImmuCell
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

ImmuCell has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$247.82M1.20-$88.13M-$0.98N/A
ImmuCell$27.64M3.73-$1.04M$0.2056.65

In the previous week, ImmuCell had 5 more articles in the media than Aurora Cannabis. MarketBeat recorded 6 mentions for ImmuCell and 1 mentions for Aurora Cannabis. ImmuCell's average media sentiment score of 0.94 beat Aurora Cannabis' score of 0.18 indicating that ImmuCell is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ImmuCell
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ImmuCell beats Aurora Cannabis on 11 of the 15 factors compared between the two stocks.

How does ImmuCell compare to Enanta Pharmaceuticals?

ImmuCell (NASDAQ:ICCC) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImmuCell has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuCell$27.64M3.73-$1.04M$0.2056.65
Enanta Pharmaceuticals$63M4.02-$81.89M-$2.41N/A

In the previous week, ImmuCell had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 6 mentions for ImmuCell and 5 mentions for Enanta Pharmaceuticals. ImmuCell's average media sentiment score of 0.94 beat Enanta Pharmaceuticals' score of -0.41 indicating that ImmuCell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmuCell
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Enanta Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

ImmuCell has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

ImmuCell has a net margin of 5.66% compared to Enanta Pharmaceuticals' net margin of -108.33%. ImmuCell's return on equity of 6.25% beat Enanta Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuCell5.66% 6.25% 4.15%
Enanta Pharmaceuticals -108.33%-59.48%-21.76%

Enanta Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 130.15%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than ImmuCell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Enanta Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Enanta Pharmaceuticals beats ImmuCell on 8 of the 15 factors compared between the two stocks.

Get ImmuCell News Delivered to You Automatically

Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ICCC vs. The Competition

MetricImmuCellPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$103.82M$13.74B$7.82B$11.74B
Dividend YieldN/A2.58%2.47%4.47%
P/E Ratio57.1026.5832.7626.82
Price / Sales3.737.298.565.70
Price / Cash59.2315.6321.0121.90
Price / Book3.145.424.463.72
Net Income-$1.04M$2.88B$3.52B$393.10M
7 Day Performance10.43%-4.10%-5.47%-4.73%
1 Month Performance5.40%-5.08%-4.57%-7.14%
1 Year Performance130.75%-7.47%-1.79%-7.51%

ImmuCell Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICCC
ImmuCell
1.1459 of 5 stars
$11.33
-0.8%
N/A+111.5%$103.82M$27.64M57.1073
FENC
Adherex Technologies
4.7276 of 5 stars
$10.64
+0.6%
$17.00
+59.8%
+62.3%$372.57M$44.64MN/A35
SPRY
ARS Pharmaceuticals
2.5659 of 5 stars
$3.95
+10.6%
$23.33
+490.7%
-56.3%$358.89M$84.28MN/A206
AVIR
Atea Pharmaceuticals
2.6795 of 5 stars
$4.22
+0.5%
$7.00
+65.9%
+39.2%$337.28MN/AN/A55
ACB
Aurora Cannabis
0.3714 of 5 stars
$5.05
-1.2%
N/A+7.0%$335.85M$247.82MN/A1,028

Related Companies and Tools


This page (NASDAQ:ICCC) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners